Repare Therapeutics (RPTX)
(Real Time Quote from BATS)
$3.12 USD
-0.03 (-0.95%)
Updated Apr 26, 2024 02:42 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RPTX 3.12 -0.03(-0.95%)
Will RPTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RPTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPTX
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
RPTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround
Other News for RPTX
Buy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive Valuation
Repare Therapeutics reinstated with a Buy from Accumulate at Bloom Burton
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Buy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts Ahead
Repare Therapeutics to Participate in Two Upcoming Investor Conferences